FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

		or Seci	1011 30(11) 01	the investment Company Act of 18	940				
Name and Address of Reporting Person* Neal Wendy S.		2. Date of Event Requiring Statement (Month/Day/Year) 05/14/2015		3. Issuer Name and Ticker or Trading Symbol Arcadia Biosciences, Inc. [RKDA]					
(Last) (First) (Middle) C/O ARCADIA BIOSCIENCES, INC.				Relationship of Reporting Perso (Check all applicable) Director	10% Owne	er (Mo	5. If Amendment, Date of Original Filed (Month/Day/Year)		
4222 E THOMAS ROAD, SUITE 320				X Officer (give title below)	Other (specify below)		6. Individual or Joint/Group Filing (Check Applicable Line)		
(Street) PHOENIX AZ 85018				VP, Chief Legal Office			X Form filed by One Reporting Person Form filed by More than One Reporting Person		
(City) (State)	(Zip)								
		Table I - Noi	n-Derivat	tive Securities Beneficiall	y Owned				
1. Title of Security (Instr. 4)				2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownersh Form: Direct or Indirect ((Instr. 5)	ct (D) (Instr. 5)			
Common Stock				0	D				
				e Securities Beneficially ants, options, convertible		s)			
		2. Date Exerc Expiration D (Month/Day/	ate	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversior or Exercise Price of	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
		Date Exercisable	Expiration Date	n Title	Amount or Number of Shares	Price of Derivative Security Direct (D) or Indirect (I) (Instr. 5)			
Employee Stock Opti	on (right to buy)	(1)	06/30/2018	Common Stock	50,000	10.8	D		
Employee Stock Opti	on (right to buy)	(1)	10/31/2019	Common Stock	31,250	2.24	D		
Employee Stock Opti	on (right to buy)	(1)	12/31/2019	Common Stock	50,000	2.24	D		
Employee Stock Opti	on (right to buy)	(1)	12/31/2020	Common Stock	18,750	13.56	D		
Employee Stock Opti	on (right to buy)	(2)	12/31/2022	2 Common Stock	25,000	13.56	D		
Employee Stock Opti	on (right to buy)	(3)	10/29/2024	Common Stock	12,500	6.12	D		
Employee Stock Opti	on (right to buy)	(4)	02/11/2025	Common Stock	10,000	7.2	D		

Explanation of Responses:

- 1. The option is fully exercisable as of the date hereof.
- 2. The option vested as to 25% of the shares on the date of grant, with the remaining 75% of shares vesting in equal quarterly installments beginning on March 31, 2013 and ending on December 31, 2015. All unvested shares shall become fully exercisable upon the closing of the issuer's initial public offering.
- 3. The option vested as to 50% of the shares on February 7, 2015, with the remaining 50% of shares vesting in equal monthly installments beginning on February 28, 2015 and ending on January 31, 2017.
- 4. The option will vest as to 25% of the shares on February 11, 2016, with the remaining 75% of shares vesting in equal monthly installments beginning on February 29, 2016 and ending on January 31, 2019.

Remarks:

Exhibit 24.1: Power of Attorney

/s/ Wendy S. Neal

05/14/2015

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby constitutes and appoints each of Thomas P. O'Neil, Pam Haley and Sherry Mori, signing singly, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Arcadia Biosciences, Inc. (the "Company"), Forms 3, 4 and 5 (including amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules and regulations thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Forms 3, 4 or 5 and timely file such form (including amendments thereto) with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

The undersigned agrees that such attorney-in-fact may rely entirely on information furnished orally or in writing by the undersigned to such attorney-in-fact. The undersigned also agrees to indemnify and hold harmless the Company and such attorney-in-fact against any losses, claims, damages or liabilities (or actions in these respects) that arise out of or are based on any untrue statement or omission of necessary facts in the information provided by the undersigned to such attorney-in-fact for purposes of executing, acknowledging, delivering and filing Forms 3, 4 or 5 (including amendments thereto) and agrees to reimburse the Company and such attorney-in-fact for any legal or other expenses reasonably incurred in connection with investigating or defending against any such loss, claim, damage, liability or action.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 or 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier (a) revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or (b) superseded by a new power of attorney regarding the purposes outlined in the first paragraph hereof as of a later date.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 14th day of May, 2015.

/s/ Wendy S. Neal Signature Wendy S. Neal Print Name